These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25952249)

  • 1. Neurocognitive and neuroimaging outcome of early treated young adult PKU patients: A longitudinal study.
    Nardecchia F; Manti F; Chiarotti F; Carducci C; Carducci C; Leuzzi V
    Mol Genet Metab; 2015; 115(2-3):84-90. PubMed ID: 25952249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive functioning in adults with phenylketonuria: results of a long term study.
    Weglage J; Fromm J; van Teeffelen-Heithoff A; Möller HE; Koletzko B; Marquardt T; Rutsch F; Feldmann R
    Mol Genet Metab; 2013; 110 Suppl():S44-8. PubMed ID: 24071437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of white matter abnormalities in early treated phenylketonuric patients: A retrospective longitudinal long-term study.
    Mastrangelo M; Chiarotti F; Berillo L; Caputi C; Carducci C; Di Biasi C; Manti F; Nardecchia F; Leuzzi V
    Mol Genet Metab; 2015 Nov; 116(3):171-7. PubMed ID: 26283467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurocognitive functioning in adults with phenylketonuria: Report of a 10-year follow-up.
    Feldmann R; Osterloh J; Onon S; Fromm J; Rutsch F; Weglage J
    Mol Genet Metab; 2019 Mar; 126(3):246-249. PubMed ID: 30598390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.
    Jahja R; Huijbregts SC; de Sonneville LM; van der Meere JJ; Bosch AM; Hollak CE; Rubio-Gozalbo ME; Brouwers MC; Hofstede FC; de Vries MC; Janssen MC; van der Ploeg AT; Langendonk JG; van Spronsen FJ
    Mol Genet Metab; 2013; 110 Suppl():S57-61. PubMed ID: 24183792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels?
    Anderson PJ; Wood SJ; Francis DE; Coleman L; Anderson V; Boneh A
    Dev Neuropsychol; 2007; 32(2):645-68. PubMed ID: 17931123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review.
    Brumm VL; Azen C; Moats RA; Stern AM; Broomand C; Nelson MD; Koch R
    J Inherit Metab Dis; 2004; 27(5):549-66. PubMed ID: 15669671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurological, neuropsychological, and ophthalmological evolution after one year of docosahexaenoic acid supplementation in phenylketonuric patients].
    Gutiérrez-Mata AP; Vilaseca MA; Capdevila-Cirera A; Vidal-Oller M; Alonso-Colmenero I; Colomé R; López-Sala A; Lambruschini-Ferri N; Gutiérrez A; Gassió R; Artuch R; Campistol J
    Rev Neurol; 2012 Aug; 55(4):200-6. PubMed ID: 22829083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. White and gray matter brain development in children and young adults with phenylketonuria.
    Hawks Z; Hood AM; Lerman-Sinkoff DB; Shimony JS; Rutlin J; Lagoni D; Grange DK; White DA
    Neuroimage Clin; 2019; 23():101916. PubMed ID: 31491833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Executive function impairment in early-treated PKU subjects with normal mental development.
    Leuzzi V; Pansini M; Sechi E; Chiarotti F; Carducci C; Levi G; Antonozzi I
    J Inherit Metab Dis; 2004; 27(2):115-25. PubMed ID: 15159642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-Up of Cognition and Mental Health in Adult Phenylketonuria: A PKU-COBESO Study.
    Jahja R; van Spronsen FJ; de Sonneville LMJ; van der Meere JJ; Bosch AM; Hollak CEM; Rubio-Gozalbo ME; Brouwers MCGJ; Hofstede FC; de Vries MC; Janssen MCH; van der Ploeg AT; Langendonk JG; Huijbregts SCJ
    Behav Genet; 2017 Sep; 47(5):486-497. PubMed ID: 28776207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels.
    Pardo J; Capdevila-Lacasa C; Segura B; Pané A; Montserrat C; de Talló Forga-Visa M; Moreno PJ; Garrabou G; Grau-Junyent JM; Junqué C;
    J Neurodev Disord; 2024 Jun; 16(1):33. PubMed ID: 38907189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria.
    Weglage J; Ullrich K; Pietsch M; Fünders B; Güttler F; Harms E
    Pediatr Res; 1997 Sep; 42(3):378-84. PubMed ID: 9284280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria.
    Boot E; Hollak CEM; Huijbregts SCJ; Jahja R; van Vliet D; Nederveen AJ; Nieman DH; Bosch AM; Bour LJ; Bakermans AJ; Abeling NGGM; Bassett AS; van Amelsvoort TAMJ; van Spronsen FJ; Booij J
    Psychol Med; 2017 Dec; 47(16):2854-2865. PubMed ID: 28552082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White matter pathology in phenylketonuria.
    Anderson PJ; Leuzzi V
    Mol Genet Metab; 2010; 99 Suppl 1():S3-9. PubMed ID: 20123467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study.
    Jahja R; van Spronsen FJ; de Sonneville LMJ; van der Meere JJ; Bosch AM; Hollak CEM; Rubio-Gozalbo ME; Brouwers MCGJ; Hofstede FC; de Vries MC; Janssen MCH; van der Ploeg AT; Langendonk JG; Huijbregts SCJ
    J Inherit Metab Dis; 2016 May; 39(3):355-362. PubMed ID: 26914933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria.
    Huijbregts S; de Sonneville L; Licht R; Sergeant J; van Spronsen F
    Dev Neuropsychol; 2002; 22(2):481-99. PubMed ID: 12537335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychology of early-treated phenylketonuria: specific executive function deficits.
    Welsh MC; Pennington BF; Ozonoff S; Rouse B; McCabe ER
    Child Dev; 1990 Dec; 61(6):1697-713. PubMed ID: 2083493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU.
    Diamond A; Prevor MB; Callender G; Druin DP
    Monogr Soc Res Child Dev; 1997; 62(4):i-v, 1-208. PubMed ID: 9421921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive functioning in children and adolescents with phenylketonuria.
    VanZutphen K; Packman W; Sporri L; Needham M; Morgan C; Weisiger K; Packman S
    Clin Genet; 2007 Jul; 72(1):13-8. PubMed ID: 17594394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.